Monday, November 24, 2025 4:19:39 PM
NWBO bought Advent for a very reasonable sum. Then you started dissing Advent as worthless.
Nope. I asserted the book value is either negligible or negative. We will see come next year if I am right. Either way. if you cannot understand the difference between book value and "value", that is on you
Ashkan was right about JAMA timing, but you weren’t.
As far as Ashkan, I have no idea exactly what you are talking about. But I would expect an author of a paper would likely know about when it was to be published. And I do not recall making any statements about when a paper would published. I admit I thought the paper would need to do a better job of explaining the trial than NYAS did if it was to be published in a major journal. Shame on JAMA IMO.
You thought the MAA was going to rejection/appeal in April. As of November 20, it was still under review and LP decided to announce beginning construction on a C suite in order to double her current capacity which means she’s planning on a transition to Eden for further scale up.
I am still virtually certain the MHRA has major objections. As far as LP building MFG, that is what she does. Means nothing for DC-L.
BTW, did you not bet me wrt MHRA approval by Feb(?) 2025? Terms were an admission you were wrong. Just like you were wrong in calling me an idiot for thinking no approval in 2024. Crickets.
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
